Treating HCC at Ochsner: A Decade Long Look at Outcomes and Why Treatment Strategy Matters for Liver Transplant Patients
With changes to transplant allocation system, hear how one institution has shifted decisions around liver cancer and liver transplant patient treatment pathways. Emphasizing the importance of the Multidisciplinary Liver Conference and incorporating innovative technologies and advances in medicine while placing a focus on liver cancer patients. Through their use of TheraSphere Y-90 Microsphere therapy they have been able to achieve durable outcomes as well as similar outcomes to other institutions who have become experts in radioembolization. Hear more about key clinical studies that supported their decision, specific case examples and further study of their own outcomes showing the impact.
For more information, please visit www.TheraSphere.com.
Product Workshop Treating HCC at Ochsner: A Decade Long Look at Outcomes and Why Treatment Strategy Matters for Liver Transplant Patients
Thumbs Up
- March 26, 2024
